Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles
- 18 May 2004
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 96 (3) , 483-495
- https://doi.org/10.1016/j.jconrel.2004.01.029
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Antisense therapy for cancer—the time of truthThe Lancet Oncology, 2002
- Albumin nanoparticles as carriers for a phosphodiester oligonucleotideInternational Journal of Pharmaceutics, 2002
- Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticlesJournal of Controlled Release, 2001
- Inhibition of HIV-1 in Cell Culture by Oligonucleotide-Loaded NanoparticlesPharmaceutical Research, 2001
- Antisense delivery using protamine-oligonucleotide particlesNucleic Acids Research, 2000
- Desolvation process and surface characterisation of protein nanoparticlesPublished by Elsevier ,1999
- Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in ratsEuropean Journal of Pharmaceutics and Biopharmaceutics, 1998
- Polyalkylcyanoacrylate Nanoparticles as Polymeric Carriers for Antisense OligonucleotidesPharmaceutical Research, 1992
- Albumin Microspheres as Vehicles for the Sustained and Controlled Release of DoxorubicinJournal of Pharmacy and Pharmacology, 1989
- Albumin microspheres. I. Release characteristics of adriamycinInternational Journal of Pharmaceutics, 1986